Global Immunology Drugs Market Outlook, 2031

The global immunology drugs industry covers medicines that modify the immune system to treat autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, atopic dermatitis, asthma, chronic obstructive pulmonary disease with type 2 inflammation, systemic lupus erythematosus, multiple sclerosis in some classifications, myasthenia gravis, hidradenitis suppurativa, chronic spontaneous urticaria and many rare immune disorders. The market is dominated by biologics and targeted small molecules. Leading products include AbbVie's Skyrizi, Rinvoq and Humira; Sanofi and Regeneron's Dupixent, which became one of the world's best-selling drugs; Johnson & Johnson's Stelara and Tremfya; Novartis's Cosentyx; Eli Lilly's Taltz, Ebglyss and Omvoh; Amgen's Enbrel, Otezla and Tezspire with AstraZeneca; UCB's Bimzelx; Bristol Myers Squibb's Sotyktu and Orencia; Pfizer's Xeljanz and Cibinqo; Galderma's Nemluvio; argenx's Vyvgart; and AstraZeneca's Saphnelo and Fasenra. Biosimilar makers such as Amgen, Sandoz, Samsung Bioepis, Celltrion, Alvotech, Biocon and Fresenius Kabi compete for off-patent biologics. Immunology is one of the largest therapeutic areas in the pharmaceutical industry, and many large companies consider it a core growth area alongside oncology and metabolic disease. The immunology market has been reshaped by the loss of exclusivity for its biggest products and the rapid rise of their successors. Humira, once the world's best-selling drug, faced biosimilar competition in Europe from 2018 and in the United States from 2023, and Stelara biosimilars arrived in 2025, while Enbrel and Stelara were among the first drugs selected for Medicare price negotiation, with lower prices from January 2026. AbbVie offset Humira's decline with Skyrizi and Rinvoq, which together exceeded Humira's peak sales, and Dupixent expanded into chronic obstructive pulmonary disease in 2024, chronic spontaneous urticaria and bullous pemphigoid in 2025, and other type 2 inflammatory diseases. Innovation has broadened with new mechanisms, including IL-13 inhibitors such as Ebglyss, the IL-31 receptor antagonist Nemluvio, TYK2 inhibitors such as Sotyktu, IL-17A and IL-17F inhibition with Bimzelx, and neonatal Fc receptor blockers such as Vyvgart, Rystiggo and Johnson & Johnson's Imaavy, approved in April 2025 for myasthenia gravis. Oral targeted therapies advanced in 2026 when the FDA approved Johnson & Johnson's icotrokinra, marketed as Icotyde, the first oral peptide that blocks the IL-23 receptor, for plaque psoriasis in March. Companies are also exploring CAR-T cell therapies and T-cell engagers to reset the immune system in lupus and other severe autoimmune diseases, and bispecific antibodies that target two inflammatory pathways at once. Market Dynamics Market Drivers • Rising Prevalence and Diagnosis of Immune-Mediated DiseasesAutoimmune and inflammatory diseases affect hundreds of millions of people globally, and conditions such as atopic dermatitis, asthma, psoriasis and inflammatory bowel disease are increasing, particularly in urbanising countries. Better awareness, earlier diagnosis and treatment guidelines recommending advanced therapies for moderate-to-severe disease increase the number of treated patients. Chronic diseases require long-term therapy, providing sustained demand for immunology drugs. • Expansion of Targeted Therapies into New IndicationsSuccessful immunology drugs are tested across many diseases that share immune pathways, extending their commercial life and patient reach. Dupixent has gained approvals in atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic oesophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria and bullous pemphigoid. IL-23 inhibitors and JAK inhibitors have expanded from psoriasis and arthritis into inflammatory bowel disease. New mechanisms continue to open previously untreated conditions to advanced therapy. Market Challenges • Biosimilar Competition and Price NegotiationBiosimilars for adalimumab, ustekinumab, etanercept, tocilizumab, infliximab and other biologics have sharply reduced prices, particularly in Europe and increasingly in the United States, where pharmacy benefit managers launched private-label biosimilars. Medicare price negotiation lowered prices for Enbrel and Stelara from 2026, and more immunology drugs are likely to be selected. Payers also require step therapy, limiting access to the newest branded treatments. • Safety Concerns and Treatment LimitationsImmunosuppressive drugs increase the risk of infections, and JAK inhibitors carry boxed warnings for cardiovascular events, blood clots, cancer and death following safety trials. Many patients do not respond to a given therapy or lose response over time, and remission rates in diseases such as lupus remain low. Long-term safety of new mechanisms must be monitored, and treatment of pregnant women and children requires additional evidence. Market Trends • Oral Targeted Therapies Challenging InjectablesOral drugs that match the efficacy of injectable biologics are a major goal. Icotrokinra, approved in March 2026, showed skin clearance rates comparable to many injectables in psoriasis, TYK2 inhibitors such as deucravacitinib and newer agents from Takeda and others target psoriasis and lupus, and oral IL-17 and TNF inhibitors are in development. Oral treatments could reach patients reluctant to use injections and shift market share away from established biologics. • Immune Reset with Cell Therapies and BispecificsCAR-T cell therapies targeting CD19 or BCMA, originally developed for blood cancers, have produced drug-free remissions in small studies of severe lupus, myositis and systemic sclerosis. Companies including Kyverna, Cabaletta, Novartis, Bristol Myers Squibb and others are conducting trials, and T-cell engaging bispecific antibodies are also being tested. Bispecific antibodies that block two cytokines, such as IL-4 and IL-13 or TNF and IL-23, aim to improve response rates. Segment Analysis Interleukin inhibitors have become the largest and fastest-growing class of immunology drugs, while TNF inhibitors remain widely used but are declining in value because of biosimilar competition. Interleukin inhibitors include IL-23 inhibitors such as risankizumab, guselkumab, tildrakizumab and mirikizumab; IL-17 inhibitors such as secukinumab, ixekizumab and bimekizumab; IL-4 and IL-13 inhibitors such as dupilumab, lebrikizumab and tralokinumab; IL-5 inhibitors such as mepolizumab and benralizumab; IL-6 inhibitors such as tocilizumab and sarilumab; the IL-12/23 inhibitor ustekinumab; and the IL-31 receptor antagonist nemolizumab. Together they represent the largest share of immunology revenue. TNF inhibitors, including adalimumab, etanercept, infliximab, certolizumab and golimumab, were the foundation of modern immunology and remain widely used, but prices have fallen sharply with biosimilars. JAK inhibitors, including upadacitinib, tofacitinib, baricitinib and abrocitinib, are oral drugs used across rheumatoid arthritis, atopic dermatitis, alopecia areata and IBD, with safety warnings limiting their position. TYK2 inhibitors, PDE4 inhibitors such as apremilast and roflumilast, S1P receptor modulators and oral peptides such as icotrokinra form growing oral segments. B-cell and T-cell targeted therapies include rituximab, belimumab and abatacept. FcRn blockers, including efgartigimod, rozanolixizumab and nipocalimab, and complement inhibitors treat antibody-mediated diseases such as myasthenia gravis. TSLP and IgE antibodies, including tezepelumab and omalizumab, treat asthma and allergic diseases. Dermatology and rheumatology indications account for the largest share of immunology drug value, while respiratory, gastrointestinal and neurological immune diseases are expanding the market. Psoriasis is one of the largest immunology indications, with many biologics and oral drugs competing and IL-23 and IL-17 inhibitors achieving high rates of skin clearance. Atopic dermatitis has become a major market since Dupixent's approval in 2017, with lebrikizumab, tralokinumab, nemolizumab and JAK inhibitors adding options, and children and adolescents represent a growing patient group. Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis are large rheumatology indications treated with TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, JAK inhibitors and abatacept. Inflammatory bowel disease is covered by several immunology drugs and is one of the fastest-growing indications. Asthma, chronic rhinosinusitis with nasal polyps and COPD with type 2 inflammation are treated with biologics targeting IgE, IL-5, IL-4 and IL-13 and TSLP. Systemic lupus erythematosus and lupus nephritis are treated with belimumab, anifrolumab and voclosporin, and remain areas of high unmet need. Hidradenitis suppurativa, chronic spontaneous urticaria, alopecia areata, vitiligo and prurigo nodularis have gained approved advanced therapies. Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and other antibody-mediated neurological diseases are growing markets for FcRn blockers and complement inhibitors. Subcutaneous injections account for the largest share of immunology drug value, while oral therapies are gaining share and intravenous infusions remain important for certain biologics and severe disease. Subcutaneous injection is the dominant route for immunology biologics, including adalimumab, etanercept, secukinumab, ixekizumab, risankizumab, guselkumab, dupilumab, lebrikizumab, bimekizumab and tezepelumab, typically given by patients at home using prefilled pens or syringes at intervals from weekly to every three months. Longer dosing intervals, such as every 12 weeks for risankizumab maintenance or every eight weeks for bimekizumab, improve convenience. Oral therapies, including JAK inhibitors, TYK2 inhibitors, PDE4 inhibitors, S1P receptor modulators, icotrokinra, methotrexate and other conventional drugs, are growing as efficacy improves and patients prefer pills. Intravenous infusions are used for infliximab, vedolizumab, tocilizumab, abatacept, rituximab, anifrolumab, efgartigimod and nipocalimab in some settings, and for induction doses of several IBD drugs, delivered in infusion centres. Topical treatments, including topical JAK inhibitors, PDE4 inhibitors, tapinarof and corticosteroids, remain important for mild to moderate skin diseases. Inhaled corticosteroids and biologics complement each other in asthma. Subcutaneous formulations of drugs originally given intravenously, such as infliximab and vedolizumab, are becoming more common. Specialty pharmacies account for the largest share of immunology drug distribution in the United States, while hospital pharmacies and national procurement systems play larger roles in Europe and Asia. Specialty pharmacies dispense most self-injected immunology biologics and many oral targeted therapies in the United States, handling prior authorisations, copay assistance, cold-chain shipping and adherence support, and they are often owned by pharmacy benefit managers or large health systems. Retail pharmacies dispense conventional immunosuppressants, topical therapies and some oral drugs. Hospital pharmacies and infusion centres supply intravenous biologics and treat severe or complex cases, and in many European countries hospitals dispense biologics even for home use. Online pharmacies and telehealth services have expanded in dermatology and allergy, particularly for chronic skin conditions. National tenders and procurement systems in Europe drive rapid biosimilar adoption, while China's national reimbursement negotiations have expanded access to biologics at lower prices. Manufacturer patient support programmes and direct-to-consumer channels provide services, sample programmes and copay cards. Physicians in dermatology, rheumatology, gastroenterology, allergy and neurology play a central role in choosing treatments, supported by guidelines and payer formularies. Regional Analysis North America leads the immunology drugs market because of high biologic use and prices, broad insurance coverage for advanced therapies and early adoption of new drugs, while Asia-Pacific is the fastest-growing region as access to biologics expands. North America, particularly the United States, accounts for the largest share of immunology drug revenue. The United States has high prevalence of psoriasis, atopic dermatitis, rheumatoid arthritis, IBD and asthma, extensive use of advanced therapies and prices well above other countries. Humira biosimilars from 2023, Stelara biosimilars from 2025 and Medicare negotiated prices for Enbrel and Stelara from 2026 have reduced revenue from older drugs, while Skyrizi, Rinvoq, Dupixent, Tremfya and Bimzelx have grown strongly. The FDA approved icotrokinra in March 2026 and Imaavy in April 2025, adding new mechanisms. Canada has high biosimilar uptake following provincial switching policies. Europe is the second largest market, with high use of biologics but lower prices, strong biosimilar adoption through tenders and health technology assessment limiting use of expensive new drugs. Asia-Pacific is the fastest-growing region. Japan has a large immunology market with high biologic use, while China has expanded access to biologics through national reimbursement negotiations and a growing domestic industry, including companies such as Akeso and Keymed Biosciences developing IL-17, IL-4R and other antibodies. India's market is growing with biosimilars from Biocon, Intas and Zydus. Latin America, led by Brazil and Mexico, relies on public procurement and biosimilars, while the Middle East, particularly Saudi Arabia and the UAE, has expanded access to advanced therapies. Key Developments March 2026: Johnson & Johnson's icotrokinra became the first oral peptide that selectively blocks the IL-23 receptor, approved for adults and adolescents with moderate to severe plaque psoriasis. January 2026: Lower Medicare prices for Enbrel and Stelara, negotiated under the Inflation Reduction Act, took effect, reducing revenue from two major immunology brands. April 2025: Johnson & Johnson's FcRn blocker was approved for generalised myasthenia gravis in adults and adolescents who are antibody-positive. January 2025: The first biosimilars to ustekinumab launched in the United States, following European launches in 2024, reducing prices for psoriasis and IBD treatment. September 2024: Dupilumab became the first biologic approved for adults with inadequately controlled chronic obstructive pulmonary disease with an eosinophilic phenotype. January 2023: Amgen's Amjevita became the first adalimumab biosimilar in the United States, followed by many others in July 2023, ending Humira's exclusivity. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global Immunology Drugs Market with its value and forecast along with its segments • Various drivers and challenges • Ongoing trends and developments • Top profiled companies • Strategic recommendation By Drug Class • Interleukin Inhibitors • TNF Inhibitors • JAK and TYK2 Inhibitors • Other Oral Targeted Therapies • B-Cell and T-Cell Targeted Therapies • FcRn Blockers and Complement Inhibitors By Indication • Psoriasis and Psoriatic Arthritis • Atopic Dermatitis • Rheumatoid Arthritis and Spondyloarthritis • Inflammatory Bowel Disease • Asthma and COPD • Lupus and Other Autoimmune Diseases By Route of Administration • Subcutaneous • Oral • Intravenous • Topical By Distribution Channel • Specialty Pharmacies • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now